Benjamin Solomon
A5045959942- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Head and Neck Cancer Studies
- Cancer, Hypoxia, and Metabolism
- Gastric Cancer Management and Outcomes
- Lymphoma Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- RNA modifications and cancer
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Telomeres, Telomerase, and Senescence
- Epigenetics and DNA Methylation
- HER2/EGFR in Cancer Research
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Neuroendocrine Tumor Research Advances
- Medical Imaging Techniques and Applications
- Thyroid Cancer Diagnosis and Treatment
Peter MacCallum Cancer Centre
2016-2025
The University of Melbourne
2016-2025
Addis Ababa University
2025
Guangdong Academy of Medical Sciences
2018-2024
Cancer Services
2024
U-M Rogel Cancer Center
2020-2024
Imperial College London
2024
Southern Medical University
2024
Fudan University
2024
Zhongshan Hospital
2024
Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup non-small-cell lung cancers, representing 2 to 7% such tumors. We explored the therapeutic efficacy inhibiting ALK tumors an early-phase clinical trial crizotinib (PF-02341066), orally available small-molecule inhibitor tyrosine kinase.After screening tumor samples from approximately 1500 patients with cancer for presence rearrangements, we identified 82 advanced ALK-positive disease who...
In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral tyrosine inhibitor targeting ALK. Whether crizotinib is superior standard chemotherapy respect efficacy unknown.
The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown.We conducted an open-label, phase 3 trial comparing in 343 patients nonsquamous NSCLC who had received no previous systemic disease. Patients were randomly assigned to receive oral at a dose 250 mg twice daily or intravenous (pemetrexed, 500 per square meter body-surface area, plus either cisplatin, 75 meter,...
The EML4-ALK fusion oncogene represents a novel molecular target in small subset of non-small-cell lung cancers (NSCLC). To aid identification and treatment these patients, we examined the clinical characteristics outcomes patients who had NSCLC with without EML4-ALK.Patients were selected for genetic screening on basis two or more following characteristics: female sex, Asian ethnicity, never/light smoking history, adenocarcinoma histology. was identified by using fluorescent situ...
Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) define a distinct molecular subgroup non-small-cell lung cancers (NSCLCs) that may be susceptible to therapeutic inhibition. Crizotinib is small-molecule inhibitor anaplastic lymphoma (ALK), ROS1, and another kinase, MET.
Non-small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) a new that has shown greater antitumor potency than crizotinib in preclinical studies.In this phase 1 study, we administered oral ceritinib doses of 50 750 mg once daily patients with advanced cancers genetic alterations ALK. In an expansion received maximum tolerated dose. Patients were assessed...
Multiple mechanisms of crizotinib resistance were identified in lung cancer patients including new secondary ALK mutations and activation receptor tyrosine kinases.
Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non–small-cell lung cancer (NSCLC). The efficacy lorlatinib, as compared that crizotinib, first-line treatment for advanced NSCLC is unclear.
FGFR1 amplification provides a therapeutic target for squamous cell lung cancer, which is resistant to other targeted cancer drugs.
Context.— In 2013, an evidence-based guideline was published by the College of American Pathologists, International Association for Study Lung Cancer, and Molecular Pathology to set standards molecular analysis lung cancers guide treatment decisions with targeted inhibitors. New evidence has prompted evaluation additional laboratory technologies, targetable genes, patient populations, tumor types testing. Objective.— To systematically review update 2013 affirm its validity; assess new...
To determine the prognostic importance of p16 and human papillomavirus (HPV) in patients with oropharyngeal cancer treated on a phase III concurrent chemoradiotherapy trial.Patients stage or IV head neck squamous cell were randomly assigned to radiotherapy cisplatin without tirapazamine. In this substudy, analyses restricted cancer. was detected by immunohistochemistry, HPV situ hybridization polymerase chain reaction.Slides available for assay 206 465 patients, which 185 eligible, evaluable...
RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with fusion-positive NSCLC, the efficacy and safety selective inhibition unknown.We enrolled advanced NSCLC who had previously received platinum-based chemotherapy those were untreated separately a phase 1-2 trial selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by independent review committee. Secondary points included duration...
Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by T790M most cases. Rociletinib (CO-1686) an inhibitor active preclinical models of EGFR-mutated NSCLC or without T790M.In this phase 1-2 study, we administered rociletinib patients who had disease progression during previous treatment existing inhibitor. In expansion (phase 2) part T790M-positive received...
RET mutations occur in 70% of medullary thyroid cancers, and fusions rarely other cancers. In patients with RET-altered the efficacy safety selective inhibition are unknown.
Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged non-small-cell lung cancer (NSCLC). The clinical benefits crizotinib in patients with brain metastases have not been previously studied.Patients advanced NSCLC enrolled onto trial PROFILE 1005 or 1007 (randomly assigned to crizotinib) were included this retrospective analysis. Patients asymptomatic (nontarget target lesions) allowed enroll. Tumor assessments evaluated every 6 weeks using RECIST (version...